Warum werden zu wenige Patienten mit kolorektalen Lebermetastasen zur Resektion vorgestellt?

Why are too few patients with colorectal liver metastases submitted to resection?


Die Resektion kolorektaler Lebermetastasen (CRLM) im Rahmen eines multimodalen Therapiekonzeptes ist ein allgemein akzeptierter, potenziell kurativer Behandlungsansatz. Trotz der Tatsache, dass die Leberchirurgie eine Überlebensverlängerung für die Patienten bei guter Lebensqualität darstellt, wird diese Therapieoption bei weitem nicht allen Patienten angeboten. Der Beitrag fasst Ergebnisse der Leberresektion bei CRLM-Patienten zusammen und diskutiert Gründe für die unterschiedliche Einschätzung der Resektabilität selbst durch erfahrene Leberchirurgen. Die Komplexität der Behandlung wird exemplarisch an einem Fall aufgezeigt.


The resection of colorectal liver metastases (CRLM) within the framework of a multimodal treatment concept is a generally accepted and potentially curative treatment approach. Despite the fact that liver surgery represents a survival extension for patients with a good quality of life, this treatment option is offered to nowhere near all patients. This article summarizes the results of liver resection for CRLM patients and discusses the reasons for the different estimations of resectability even by experienced liver surgeons. The complexity of the treatment is exemplarily shown based on a case report.

This is a preview of subscription content, access via your institution.

Abb. 1
Abb. 2
Abb. 3


  1. 1.

    Adam R, Laurent A, Azoulay D et al (2000) Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 232:777–785. https://doi.org/10.1097/00000658-200012000-00006

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Albertsmeier M, Riedl K, Stephan A‑J et al (2020) Improved survival after resection of colorectal liver metastases in patients with unresectable lung metastases. HPB 22:368–375. https://doi.org/10.1016/j.hpb.2019.07.004

    Article  PubMed  Google Scholar 

  3. 3.

    Azoulay D, Castaing D, Adam R et al (2000) Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 231:480–486

    CAS  Article  Google Scholar 

  4. 4.

    Brouquet A, Abdalla EK, Kopetz S et al (2011) High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29:1083–1090. https://doi.org/10.1200/jco.2010.32.6132

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Capobianco I, Strohäker J, Penna AD et al (2019) Präkonditionierung der Leber. Chirurg 90:542–547. https://doi.org/10.1007/s00104-019-0926-0

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Creasy JM, Sadot E, Koerkamp BG et al (2018) Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 163:1238–1244. https://doi.org/10.1016/j.surg.2018.01.004

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Filmann N, Walter D, Schadde E et al (2019) Mortality after liver surgery in Germany. Br J Surg 106:1523–1529. https://doi.org/10.1002/bjs.11236

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311–1319. https://doi.org/10.1093/annonc/mdi246

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47. https://doi.org/10.1016/s1470-2045(09)70330-4

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Guiu B, Quenet F, Escal L et al (2017) Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. Eur Radiol 27:3343–3352. https://doi.org/10.1007/s00330-017-4744-9

    Article  PubMed  Google Scholar 

  11. 11.

    Hackl C, Neumann P, Gerken M et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810. https://doi.org/10.1186/1471-2407-14-810

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Huiskens J, Bolhuis K, Engelbrecht MR et al (2019) Outcomes of resectability assessment of the Dutch colorectal cancer group liver metastases expert panel. J Am Coll Surg 229:523–532.e2. https://doi.org/10.1016/j.jamcollsurg.2019.08.1445

    Article  PubMed  Google Scholar 

  13. 13.

    Ignatavicius P, Oberkofler CE, Chapman WC et al (2020) Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice? Ann Surg 272:715–722. https://doi.org/10.1097/sla.0000000000004331

    Article  PubMed  Google Scholar 

  14. 14.

    Lordan JT, Karanjia ND, Quiney N et al (2009) A 10-year study of outcome following hepatic resection for colorectal liver metastases—the effect of evaluation in a multidisciplinary team setting. European J Surg Oncol 35:302–306. https://doi.org/10.1016/j.ejso.2008.01.028

    CAS  Article  Google Scholar 

  15. 15.

    Mohammad WM, Martel G, Mimeault R et al (2012) Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB 14:291–297. https://doi.org/10.1111/j.1477-2574.2012.00440.x

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Nathan H, Bridges JF, Cosgrove DP et al (2012) Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Ann Surg Oncol 19:3668–3676. https://doi.org/10.1245/s10434-012-2564-3

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215. https://doi.org/10.1016/s1470-2045(13)70447-9

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Nordlinger B, Sorbye H, Glimelius B, Poston GJ (2008) ScienceDirect.com—The Lancet—perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):P1007–1016. https://doi.org/10.1016/S0140-6736(08)60455-9

  19. 19.

    Oldhafer KJ, Stavrou GA, van Gulik TM (2016) ALPPS—where do we stand, where do we go?: eight recommendations from the first international expert meeting. Ann Surg 263:839–841. https://doi.org/10.1097/sla.0000000000001633

    Article  PubMed  Google Scholar 

  20. 20.

    Petrowsky H, Linecker M, Raptis DA et al (2020) First long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases. Ann Surg 272:793–800. https://doi.org/10.1097/sla.0000000000004330

    Article  PubMed  Google Scholar 

  21. 21.

    Poston GJ, Tait D, O’Connell S et al (2011) Diagnosis and management of colorectal cancer: summary of NICE guidance

    Google Scholar 

  22. 22.

    Rahbari NN, Birgin E, Bork U et al (2021) Anterior approach vs conventional hepatectomy for resection of colorectal liver metastasis. JAMA Surg. https://doi.org/10.1001/jamasurg.2020.5050

    Article  PubMed  Google Scholar 

  23. 23.

    Renfro LA, Goldberg RM, Grothey A et al (2017) Clinical calculator for early mortality in metastatic colorectal cancer: an analysis of patients from 28 clinical trials in the aide et recherche en cancérologie digestive database. J Clin Oncol 35:1929–1937. https://doi.org/10.1200/jco.2016.71.5771

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Sawada Y, Sahara K, Endo I et al (2020) Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 27:810–818. https://doi.org/10.1002/jhbp.810

    Article  PubMed  Google Scholar 

  25. 25.

    Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastases. World J Surg 19:59–71

    CAS  Article  Google Scholar 

  26. 26.

    Stintzing S, Miller-Phillips L, Modest DP et al (2017) Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE‑3 (AIO KRK-0306) study. Eur J Cancer 79:50–60. https://doi.org/10.1016/j.ejca .2017.03.023

    CAS  Article  Google Scholar 

  27. 27.

    Strohäker J, Königsrainer A, Nadalin S (2019) Rolle des Radiologen in der Chirurgie kolorektaler Lebermetastasen. Radiologe 59:791–798. https://doi.org/10.1007/s00117-019-0577-7

    Article  PubMed  Google Scholar 

  28. 28.

    Tiernan J, Briggs C, Irving G et al (2010) Evaluation of the introduction of a standardised protocol for the staging and follow-up of colorectal cancer on resection rates for liver metastases. Ann R Coll Surg Engl 92:225–230. https://doi.org/10.1308/003588410x12628812458419

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580. https://doi.org/10.1200/jco.2007.11.0833

    Article  PubMed  Google Scholar 

  30. 30.

    Uppal A, Smieliauskas F, Sharma MR et al (2020) Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer 126:281–292. https://doi.org/10.1002/cncr.32529

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Dr. med. Dr. habil G. A. Stavrou.

Ethics declarations


G.A. Stavrou, O. Ghamarnejad und K.J. Oldhafer geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stavrou, G.A., Ghamarnejad, O. & Oldhafer, K.J. Warum werden zu wenige Patienten mit kolorektalen Lebermetastasen zur Resektion vorgestellt?. Chirurg (2021). https://doi.org/10.1007/s00104-021-01363-3

Download citation


  • Überlebensvorteil
  • Resektionsrate
  • Resektabilität
  • Metastasen
  • Fallzahlen


  • Survival benefit
  • Resection rate
  • Resectability
  • Metastases
  • Case numbers